A randomized, multiple ascending doses, clinical trial to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of CV-01 after double-blind, placebo-controlled multiple oral administrations for 2 weeks in healthy volunteers, and multiple oral administrations open-label for 2 weeks in a cohort of participants with drug resistant epilepsy

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 36
• 2 sites in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy volunteers and for adults with drug resistant epilepsy to test the safety and effects of CV-01 taken by mouth for 2 weeks.

Age

18 years or older

Sex

Men and women can join.

Disease stage

Drug resistant epilepsy (one group of the trial). Healthy volunteers can also join.

Read by machine on 9 Nov 2026.

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details